MedEdTalks - Ophthalmology

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with retinal vein occlusion.

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with neovascular age-related macular degeneration, dry age-related macular degeneration, and geographic atrophy.

In this podcast, expert clinicians will discuss current and future approaches for the management of patients with diabetic eye disease.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.

Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4.

Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3.

Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2.

Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1.